218 results match your criteria Recent Patents on Cardiovascular Drug Discovery [Journal]


Understanding basic muscle electrophysiology while keeping an eye on diseases of the heart, lung and blood.

Authors:
Raouf A Khalil

Recent Pat Cardiovasc Drug Discov 2014 ;9(1)

Harvard Medical School Brigham and Women's Hospital Division of Vascular Surgery 75 Francis Street Boston, Massachusetts 02115.

View Article

Download full-text PDF

Source
September 2015
3 Reads

Specific antidotes in development for reversal of novel anticoagulants: a review.

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):2-10

Division of Pharmacology and Clinical Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Medical Devices (AEMPS), Parque Empresarial "Las Mercedes", Edificio 8, C/ Campezo 1, Madrid, 28022, Spain.

In the last decade, several direct oral anticoagulants (DOAC; dabigatran, rivaroxaban, apixaban, edoxaban) have been marketed for prophylaxis and/or treatment of thromboembolism without having specific antidotes available for their reversal. Current management of bleeding associated to DOAC includes the removal of all antithrombotic medications and supportive care. Non-specific procoagulant agents (prothrombin complex concentrates and activated factor VIIa) have been used in case of serious bleeding. Read More

View Article

Download full-text PDF

Source
September 2015
35 Reads

Pulmonary hypertension in the perioperative period-focus on current and emerging therapies.

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):38-50

Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, Mayo Clinic, Phoenix, Arizona, USA.

Patients with pulmonary hypertension continue to present for both cardiac and non-cardiac surgery in greater numbers worldwide, and are usually managed by cardiothoracic anesthesiologists. These specialists have traditionally used intravenous therapy in the operating room to manipulate hemodynamics (cardiac output systemic and pulmonary vascular resistance), to effectively manage these high risk patients. General anesthesia involves the administration of both intravenous and inhaled drug therapy to achieve the desired goals, i. Read More

View Article

Download full-text PDF

Source
September 2015
3 Reads

Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift?

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):11-21

Department of Medicine, University of Florida, 1600 SW Archer Road, PO BOX 100277, Gainesville, FL, 32610; USA.

Beta-adrenergic blockers remain one of the cornerstones in the management of coronary artery disease, both in chronic stable angina and myocardial infarction. These recommendations were based on studies conducted in the era prior to the establishment of the modern therapy for ischemic heart disease and myocardial infarction i.e. Read More

View Article

Download full-text PDF

Source
September 2015
5 Reads
2 Citations

Ticagrelor: a novel drug for an old problem.

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):51-7

Coronary Care Unit and Catheterization Laboratory, "Maggiore della Carità" Hospital, Corso Mazzini 18, 28100 Novara, Italy.

Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST - segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Read More

View Article

Download full-text PDF

Source
September 2015
9 Reads

Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):28-37

State Medical School of São Jose do Rio Preto/SP (FAMERP), Av Brig Faria Lima 5416 - Postal Code: 15090-000, Sao Jose do Rio Preto/SP/Brazil.

Heart Failure (HF) is a progressive and fatal disorder, which ranks among the major public health problems in Brazil and worldwide. However, survival for patients who developed the syndrome after myocardial infarction (MI) enhanced significantly, as a result of an improvement of pharmacological therapies. A medical breakthrough was the discovery that remodelling of the left ventricle (LV) may be limited by the blockade of the renin-angiotensin system (RAS), at the level of angiotensin converting enzyme (ACE) and binding of angiotensin (Ang) II to its AT1 receptor. Read More

View Article

Download full-text PDF

Source
September 2015
2 Reads

New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel.

Recent Pat Cardiovasc Drug Discov 2014 ;9(1):22-7

New reversible inhibitors of platelets P2Y12 receptor, Piazzale Spedali civili, 1, 25100 Brescia, Italy.

The activation and aggregation of platelets at sites of vascular injury or near to implanted stent are pivotal in the development of thrombotic events during and after an acute coronary syndrome (ACS) or a percutaneous coronary intervention (PCI). For that reason, an exclusively oral dual antiplatelet treatment regimen with platelet P2Y12 receptor antagonists in addition to the cyclooxygenase inhibitor aspirin has become the cornerstone of treatment in that contest. However, every trial underlines the same problem: if maximizing antiplatelet therapy significantly attenuates ischemic events in patients with coronary artery disease, on the other side it may also increase bleeding phenomena. Read More

View Article

Download full-text PDF

Source
September 2015
6 Reads

Novel antidepressant drugs, arterial hypertension and cardiovascular disease.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):178-85

Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.

Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. Read More

View Article

Download full-text PDF

Source
December 2013
8 Reads

Steerable sheath technology in the ablation of atrial fibrillation.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):171-7

Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, United Kingdom.

Steerable sheaths have been shown to reduce procedure time in the catheter ablation of atrial fibrillation (AF), where catheter positioning and stability is typically challenging. This review critically addresses and highlights the recent developments in design of sheaths used to manipulate the ablation catheter and how these developments may impact on the ablation procedure itself, in particular the likelihood of first-time success. Patents relating to steerable sheaths are reviewed and discussed to gauge potential future developments in this area. Read More

View Article

Download full-text PDF

Source
December 2013
8 Reads

A novel design of combining the angiotensin converting enzyme (ACE) inhibitor captopril with the angiotensin receptor blocker (ARB) losartan using homo coupling via PEG diacid linker.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):221-5

University of Arizona Sarver Heart Center, 6119 North Pinchot, Tucson, AZ,USA 85750.

Cardiovascular disease is the leading cause of death in American adults. Furthermore, the incidence of congestive heart failure is on the rise as a major cause of hospitalization and mortality in this population. Angiotensin Converting Enzyme (ACE) inhibitors prevent the production of angiotensin II, which has been shown to reduce mortality in patients with congestive heart failure. Read More

View Article

Download full-text PDF

Source
December 2013
3 Reads

Patents and Heart Valve Surgery - III: Percutaneous Heart Valves.

Recent Pat Cardiovasc Drug Discov 2014 Jan 23. Epub 2014 Jan 23.

Director of Clinical Research and Innovations, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, 110 S Paca Street, 7th Floor, Baltimore, MD, 21201, USA & Laboratorio di Ingegneria Tissutale Cardiovascolare, Centro CardiologicoMonzino - IRCCS, via PAREA 4, 20138, Milan, Italy.

Advancements in technology for the treatment of valvularcardiac diseases seek to provide solutions for high risk patients in the form of percutaneous valve insertion for patients with complicated valvular disease not amenable to more traditional options. Within the last decade, cardiac valves designed for percutaneous insertion have emerged rapidly as a treatment option for valvular disease. This procedure serves as an alternative to open heart surgery, which is more invasive and requires longer ICU stay. Read More

View Article

Download full-text PDF

Source
January 2014
8 Reads

Canagliflozin: a new hope in the antidiabetic armamentarium.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):216-20

Cardiology Department, Hippocratio Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.

Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. Read More

View Article

Download full-text PDF

Source
December 2013
20 Reads

Need for ongoing anti arrhythmic drugs after ablation of atrial fibrillation. Review.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):204-15

Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

Ablation of atrial fibrillation (AF) is increasingly common. Newer techniques have been developed and indications broadened to a greater number of patients with drug-resistant AF. The first end point of ablation is to cure AF without further need for Anti Arrhythmic Drugs (AADs), but the success rate at 1 year and over, after a single procedure, though higher than the success rate of AADs alone, is not 100% yet. Read More

View Article

Download full-text PDF

Source
December 2013
20 Reads

Recently patented transcatheter aortic valves in clinical trials.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):186-91

Department of Cardiothoracic Surgery, Cornell University Medical Center, Weil Cornell College of Medicine, 525 68th street, New York, NY 10065, USA.

The most widely used heart valve worldwide is the Edwards Sapien, which currently has 60% of the worldwide transcatheter aortic valve implantation (TAVI) market. The CoreValve is next in line in popularity, encompassing 35% of the worldwide TAVI market. Although these two valves dominate the TAVI market, a number of newer transcatheter valves have been introduced and others are in early clinical evaluation. Read More

View Article

Download full-text PDF

Source
December 2013
6 Reads

Ranolazine: effects on ischemic heart.

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):197-203

Coronary Care Unit and Catheterization Laboratory, "Maggiore della Carita" Hospital, Corso Mazzini 18, 28100 Novara, Italy.

Coronary artery disease is the major cause of mortality and morbidity in the industrialized countries; in the United States of America and in Europe, it is responsible for one of every six deaths per year. In the setting of ischemic heart disease, angina pectoris and chest pain, in particular, are the major causes of emergency department accesses. Angina pectoris is a clinical syndrome characterized by discomfort typically in the chest, neck, chin and left arm induced by physical exertion, emotional stress and cold and is relieved by rest or by taking of nitrates. Read More

View Article

Download full-text PDF

Source
December 2013
24 Reads

A review of intracoronary abciximab in percutaneous coronary interventions--where are we now and where do we go from here?

Recent Pat Cardiovasc Drug Discov 2013 Dec;8(3):192-6

Chairman, Dept of Medicine, Bakersfield Heart Hospital, 2901 Sillect Ave #100, Bakersfield, CA, USA 93308.

The rationale for intracoronary administration of abciximab is discussed. The data on use of intracoronary abciximab in percutaneous coronary interventions in acute coronary syndromes and STEMI are reviewed. Evaluation of the niche where intracoronary administration of abciximab may be useful and future research into the subject and relevant patents are discussed. Read More

View Article

Download full-text PDF

Source
December 2013
13 Reads

Antioxidant treatment and endothelial dysfunction: is it time for flavonoids?

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):81-92

Athens University Medical School, Hippokration Hospital, Vasilisis Sofias 114, 115 28 Athens, Greece.

Endothelial dysfunction represents an imbalance between vasodilatory and vasoconstrictory molecules secreted by endothelium. Oxidative stress is a major factor leading to endothelial dysfunction with significant prognostic implications for cardiovascular events. The generation of reactive oxygen species is strongly related to various oxidase enzymes such as xanthine oxidase, uncoupled endothelial nitric oxide synthase, cyclooxygenase, glucose oxidase, lipooxygenase, nicotinamide-adenine dinucleotide phosphate oxidase and to mitochondrial electron transport mechanisms. Read More

View Article

Download full-text PDF

Source
August 2013
16 Reads

T3 and cardiac myocyte cell: a theoretical model.

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):162-5

Laboratory of Experimental Surgery and Surgical Research University of Athens, Greece.

In the last decades, the outstanding role of Thyroid gland in regulating both physiological and pathological operation of cardiovascular system has been acknowledged worldwide. Three main domains of Thyroid function, that is to say, euthyroidism -hyperthyroidism-hypothyroidism, have a direct impact on cardiac response through a variety of mechanisms. Cellular pathways mediate in cardiac contractility, cardiac output, cardiac rhythm, arterial blood pressure and peripheral vessel resistance. Read More

View Article

Download full-text PDF

Source
August 2013
9 Reads

Patents and heart valve surgery - II: tissue valves.

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):127-42

Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Valvular heart disease affects millions of Americans yearly and currently requires surgical intervention to repair or replace the defective valves. Through a close-knit collaboration between physicians, scientists and biomedical engineers, a vast degree of research and development has been aimed towards the optimization of prosthetic heart valves. Although various methods have made fantastic strides in producing durable prostheses, the therapeutic efficacy of prosthetic valves is inherently limited by a dependency upon lifelong anticoagulant regimens for recipients - a difficult challenge for many in clinical setting. Read More

View Article

Download full-text PDF

Source
August 2013
4 Reads

The determinants of successful RF ablation - is measurement of tissue contact the next step?

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):151-61

John Radcliffe Hospital, Headley Way, Headington, Oxford, Oxfordshire, OX3 9DU, United Kingdom.

The assessment of tissue contact is an area undergoing much research as a means of improving the outcomes of cardiac radiofrequency ablation. This review provides an overview of RF ablation with specific reference to the relevance of good tissue contact to adequate RF lesion formation. An up-to-date review of the clinical evidence is provided, and recent patents of novel contact-sensing technologies in the field of cardiac RF ablation are presented. Read More

View Article

Download full-text PDF

Source
August 2013
5 Reads

Recent advances in antiarrhythmic drug treatment of atrial fibrillation.

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):112-26

Cardiology Clinic, Clinical Center of Serbia, 26 Visegradska, 11 000 Belgrade, Serbia.

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in clinical practice associated with significant morbidity and mortality. With the growing number of the affected individuals, the development of safe and effective treatment options for AF has become a worldwide priority. Currently available antiarrhythmic medications for the restoration and maintenance of sinus rhythm have limitations due to the modest efficacy and a potential for adverseeffects. Read More

View Article

Download full-text PDF

Source
August 2013
4 Reads

Novel uses of imaging in AF ablation.

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):93-111

Alfred Heart Centre, Alfred Hospital, Melbourne, Victoria, Australia.

AF represents a significant burden for patients, clinicians and health policy makers alike. Catheter based AF ablation is gaining an increasing role as an effective treatment for AF, capable of reducing or even eliminating the disease. AF ablation relies on isolation of arrhthymogenic triggers and alteration of the atrial substrate by carefully targeted atrial ablation, using a minimally invasive approach. Read More

View Article

Download full-text PDF

Source
August 2013
3 Reads

Novel therapies and botanical and mechanical approaches for management of cardiovascular disease.

Authors:
Raouf A Khalil

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1)

View Article

Download full-text PDF

Source
April 2013
2 Reads

Patents and heart valve surgery--I: mechanical valves.

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):17-34

Division of Cardiothoracic Surgery, College of Physicians and Surgeons of Columbia University - New York Presbyterian Hospital, New York, NY 10032, USA.

Valvular heart disease, inherited or acquired, affects more than 5 million Americans yearly. Whereas medical treatment is beneficial in the initial stages of valvular heart disease, surgical correction provides symptomatic relief and long-term survival benefits. Surgical options include either repair or replacement using mechanical or bio-prosthetic valves. Read More

View Article

Download full-text PDF

Source
April 2013
3 Reads

Sutureless aortic valve replacement using perceval s valve.

Authors:
Shahzad G Raja

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):75-80

Department of Cardiac Surgery, Harefield Hospital, London, United Kingdom.

Surgical aortic valve replacement is the treatment of choice in patients with severe symptomatic aortic valve stenosis because it provides excellent early and long-term clinical outcomes in terms of hemodynamics, valve durability, and freedom from valve-related complications. In recent years, the number of high-risk patients being referred for surgical aortic valve replacement has increased. A considerable proportion of these patients are deemed operable despite the high risk. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384242/pdf/acs-
Web Search
https://www.health.govt.nz/system/files/documents/publicatio
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384261/pdf/acs-
Web Search
August 2013
8 Reads

Novel therapeutic strategies for the homozygous familial hypercholesterolemia.

Recent Pat Cardiovasc Drug Discov 2013 Aug;8(2):143-50

Dyslipidemia Center A.O. Ospedale Niguarda Cà Granda, Piazza Ospedale Maggiore 3, 20162, Milan - Italy.

HoFH is an autosomal co-dominant disease with a prevalence of one in 1,000,000. Mutations of LDL-R gene are responsible for this disease. HoFH needs to be distinguished from autosomal recessive hypercholesterolemia protein (ARH) that causes a similar clinical phenotype. Read More

View Article

Download full-text PDF

Source
August 2013
3 Reads

Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):2-9

Cardiovascular Department, Ferrarotto Hospital, University of Catania, Italy.

Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. Read More

View Article

Download full-text PDF

Source
April 2013
6 Reads

Advances in irrigated tip catheter technology for treatment of cardiac arrhythmias.

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):10-6

Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Radiofrequency catheter ablation without active cooling of the catheter tip is associated with significantly increased risk of thrombus formation and thromboembolism, especially when multiple and high-energy deliveries are considered. Therefore, irrigation of the distal electrode has become obligatory for catheter ablation of complex cardiac arrhythmias. The advancement in the cooling catheter technology is aimed to further reduce the risk of steam pop as well as coagulum formation on both electrode and tissue, and to maximize energy transfer to the tissue. Read More

View Article

Download full-text PDF

Source
April 2013
5 Reads

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):35-41

Cardiology Department, Hippokration Hospital, Athens, Greece.

Obesity is a major public health concern associated with increased morbidity and mortality. Its prevalence is rising worldwide mainly due to modern lifestyle habits. Several mechanisms like inflammation, endothelial dysfunction, increased sympathetic tone, high leptin and insulin concentrations as well as enhanced thrombogenesis are implicated to the emergence and progress of cardiovascular disease. Read More

View Article

Download full-text PDF

Source
April 2013
23 Reads

The role of omega-3 polyunsaturated fatty acids supplementation in childhood: a review.

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):42-55

Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.

Dietary omega-3 polyunsaturated fatty acids (ω-3 PUFAs) benefits are not clearly defined in childhood although already well-defined in adults. Recent studies have demonstrated their positive effects on bronchial asthma, neuropsychiatric disorders and cognitive brain function in childhood. Furthermore, it has been demonstrated as a relationship between the increased incidence of childhood obesity and the role of ω-3 PUFAs in reducing the metabolic and vascular alterations induced by the fat accumulation since young age. Read More

View Article

Download full-text PDF

Source
April 2013
4 Reads

Phytoestrogens and other botanicals: on the problems of evidence-based evaluation.

Authors:
Sergei V Jargin

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):67-71

Peoples' Friendship University of Russia.

Soy is the principal plant that produces phytoestrogens, named so because they bind to the estrogen receptors, however weakly compared to the estrogens. Recent reviews concluded that there is no convincing evidence in favor of alleviation of menopausal symptoms by phytoestrogens. However, some studies suggest their efficacy. Read More

View Article

Download full-text PDF

Source
April 2013
5 Reads
1 Citation

Anti-atherosclerotic therapy based on botanicals.

Recent Pat Cardiovasc Drug Discov 2013 Apr;8(1):56-66

Institute for Atherosclerosis Research of Skolkovo Innovative Center, Moscow, Russia.

Natural products including botanicals for both therapy of clinical manifestations of atherosclerosis and reduction of atherosclerosis risk factors are topics of recent patents. Only a few recent patents are relevant to the direct antiatherosclerotic therapy leading to regression of atherosclerotic lesions. Earlier, using a cellular model we have developed and patented several anti-atherosclerotic drugs. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637943PMC
April 2013
6 Reads

Recent valves used for transluminal implantation in patients with aortic valve stenosis.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):206-15

First Department of Cardiology, Hippokration Hospital, Athens Medical School, Athens, Greece.

Aortic valve stenosis is becoming a burden to society due to the constantly aging population. After the onset of the first symptoms it usually follows an ominous route with high mortality levels even at two years without any medical intervention. The gold standard for treating aortic valve stenosis is surgical replacement; nonetheless, 30% of patients are left untreated due to increased risk of surgery. Read More

View Article

Download full-text PDF

Source
December 2012
4 Reads

Recently patented and widely used valves for transcatheter aortic valve implantation.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):196-205

Montefiore Medical Center, 3400 Bainbridge Ave, MAP 5, Department of Cardiovascular and Thoracic Surgery, Albert Einstein College of Medicine, New York, NY 10467, USA.

Aortic stenosis (AS) is a serious condition in the aging US and European populations. Management of a stenotic valve is crucial as it can become symptomatic quickly leading to ventricular deterioration and overall poor quality of life. Considering that AS is a disease of the elderly patient population, surgical intervention may not be well tolerated by some patients. Read More

View Article

Download full-text PDF

Source
December 2012
2 Reads

Editorial: management of perioperative systemic inflammation during cardiopulmonary bypass: we need a multimodal approach.

Authors:
David Faraoni

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):163-4

View Article

Download full-text PDF

Source
December 2012
2 Reads

Routine use of corticosteroids to prevent inflammation response in cardiac surgery.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):170-4

Department for Anaesthesiology, Ludwig-Maximilians-University Munich, Germany.

Cardiac surgery, especially if it involves cardiopulmonary bypass, is associated with a severe systemic inflammatory response. It is characterized by complement activation and initiation of coagulation, fibrinolysis and kallikrein cascades. Consecutive activation of immunoregulatory cells results in an extensive release of pro- and anti-inflammatory cytokines. Read More

View Article

Download full-text PDF

Source
December 2012
4 Reads

Review of the fibrinolytic system: comparison of different antifibrinolytics used during cardiopulmonary bypass.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):175-9

Department of Anesthesiology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Antifibrinolytic agents are often used in different clinical situations, especially in cardiac surgery. During several years, aprotinin was the drug of choice because more than antifibrinolytic properties, aprotinin offers a direct effect on kallikrein and inflammatory pathways. In 2008, The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) initiated a discussion about real risks associated with aprotinin administration. Read More

View Article

Download full-text PDF

Source
December 2012
6 Reads

Recent advances in the comprehension and the management of perioperative systemic host response during cardiopulmonary bypass.

Authors:
Filip De Somer

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):180-5

University Hospital Gent, Heart Centre 5E-K12, De Pintelaan 185, B-9000 Gent, Belgium.

Cardiac surgery with cardiopulmonary induces a systemic inflammatory response (SIRS). SIRS is broadly defined as an inflammatory state of the whole body without a proven source of infection. Many pre and postoperative variables have been defined that have a negative impact on SIRS. Read More

View Article

Download full-text PDF

Source
December 2012
2 Reads

Actual knowledge of systemic inflammation reaction during cardiopulmonary bypass.

Authors:
Asmae Belhaj

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):165-9

Department of cardio-pulmonary transplantation, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik, 808. 1070 Brussels, Belgium.

Systemic inflammation response is a complex physiopathological host response following aggression. This phenomenon is well described during cardiac surgery under cardiopulmonary bypass but also in the context of off-pump cardiac surhery. The goal of this article is to review the different mechanisms involved in the systemic inflammation response, abusively called "systemic inflammatory response syndrome". Read More

View Article

Download full-text PDF

Source
December 2012
1 Read

Improving RBC K transport and hemoglobin-O2 binding by amiloride: A novel therapeutic approach for reversion of angina and myocardial ischemia in coronary heart diseases.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):221-35

The Clinical Research Unit, Instituto Docente de Urologia, 4th Floor, Office 419. Av. Carabobo, Urb. LaViña, Valencia 2001, Venezuela.

Unlabelled: Coronary heart disease (CHD) is the leading cause of morbidity and mortality across the entire world, in which reversion of angina or improvement of ECG remains an unrealistic therapeutic option for most patients, suggesting that microvascular dysfunction or impaired oxygen delivery might be critical factors in CHD. This research article, thus presents the rationale basis, clinical and experimental, for the first therapeutic innovation addressing the role of red blood cell (RBC) H/K and O2/CO2 exchanges in CHD. It is followed by a randomized single-blind trial of Amiloride and Optimal Medical Therapy (OMT, n=35 cases) vs OMT alone (n=35 cases) in patients having angina, ST-T alteration and a defective RBC-K transport. Read More

View Article

Download full-text PDF

Source
December 2012
2 Reads

Tools and procedures for ex vivo vein arterialization, preconditioning and tissue engineering: a step forward to translation to combat the consequences of vascular graft remodeling.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):186-95

Dipartimento di Bioingegneria, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milan, Italy.

The present contribution reviews recent progress in bioengineering approaches used to mimic arterial hemodynamic conditions in vascular grafts and vessel substitutes used in vascular surgery. While implantation of vascular bypasses is still the primary option for cardiac and vascular surgeons to recover blood perfusion in cardiac and peripheral ischemic tissues, effective techniques to reduce the impact of post-grafting vascular remodeling are insufficient. In our view, the design of specific bioreactors to perform vascular conditioning with complex stimulation patterns will provide valuable tools for comprehensive molecular analysis of vessel arterialization process. Read More

View Article

Download full-text PDF

Source
December 2012
6 Reads

Use of recombinant factor VII in cardiac surgery.

Recent Pat Cardiovasc Drug Discov 2012 Dec;7(3):216-20

University of Illinois at Chicago and Medical Director, Cardiovascular Thoracic Surgery, Weiss Memorial Hospital, 4646 N Marine Dr., Chicago, IL, 60640, USA.

The off-label use of recombinant human coagulation factor VIIa has been increasing to a number of different treatment areas since its original approval in 1999. Several US patents describe claims for FVIIa utilization in nonhemophilia patients, treatment of bleeding due to trauma, as a means to reverse major bleeding, including intracranial bleeding, induced from fibrinolytic therapy as well as a patent for using FVIIa in the treatment of bleeding for patients with bleeding disorders not caused by hemophilia, but rather bleeding disorders due to thrombocytopenia, platelet disorders, and von Willebrand's disease. Bleeding after cardiac surgery remains a serious complication that can increase both morbidity and mortality. Read More

View Article

Download full-text PDF

Source
December 2012
3 Reads

Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.

Authors:
Shahzad G Raja

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):100-4

Harefield Hospital, London, United Kingdom.

Multiple cell types in the vascular wall rely upon the rho-kinase (ROCK) signaling pathway for homeostatic function and response to injury. These cell types include endothelial and vascular smooth muscle cells, inflammatory cells, and fibroblasts. Rho is a guanosine triphosphate binding protein that activates its downstream target rho-kinase, in response to activation of a variety of G-protein coupled receptors. Read More

View Article

Download full-text PDF

Source
August 2012
3 Reads

Cardiovascular effects of green tea catechins: progress and promise.

Authors:
Mohammed A Islam

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):88-99

LECOM School of Pharmacy, Bradenton, FL 34211, USA.

Recently, there is a growing interest in the cardiovascular beneficial effects of green tea. Epidemiological and clinical studies have suggested that consumption of green tea is inversely associated with the risk of developing cardiovascular diseases. Catechins, the major flavonoid constituents of green tea, exert cardioprotective effects through diverse mechanisms that include reversal of endothelial dysfunctions, decreasing inflammatory biomarkers, and providing antioxidant, antiplatelet and antiproliferative effects. Read More

View Article

Download full-text PDF

Source
August 2012
16 Reads

Beta-blockers in intensive care medicine: potential benefit in acute brain injury and acute respiratory distress syndrome.

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):141-51

Department of Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands.

Sympathetic activation is a well-known phenomenon after acute brain injury and in critical illness. In this review we describe pathophysiological considerations that may help in elucidating the potential role of beta (β)-adrenergic antagonists to block some of the adverse sympathetic effects in acute brain injury (subarachnoid hemorrhage and traumatic brain injury) and the acute respiratory distress syndrome. In acute brain injury cardiac dysfunction has been studied most extensively but its pathophysiology is only partly elucidated in man. Read More

View Article

Download full-text PDF

Source
August 2012
27 Reads

Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus.

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):152-9

Bakersfield Heart Hospital, Bakersfield, CA 93308, USA.

Unlabelled: Slow flow and no-reflow phenomenon (SF-NR) in saphenous vein grafts (SVG) stenting is related to the occurrence of distal plaque embolization, platelet activation and microvascular vasospasm. Our article discusses few of the patents related to strategies for preventing slow-flow/no-reflow phenomenon in SVG percutaneous coronary intervention (SVG PCI).

Methods: Data from 163 consecutive patients who underwent PCI of SVG lesions without visible macro-thrombus without use of distal embolic protection device over a 10-year period were reviewed. Read More

View Article

Download full-text PDF

Source
August 2012
3 Reads

Repair of dilated aortic root and sinotubular junction using a stabilizer ring.

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):134-40

Albert-Einstein College of Medicine, Montefiore Medical Center, Department of Cardiothoracic Surgery, New York, NY, USA.

Aortic root aneurysm and dissection are potentially life-threatening conditions that involve a structural weakness of the aortic wall. Management of aortic root aneurysm (with or without aortic insufficiency) has recently been the subject of much scholarly discussion which resulted in some modifications. The current trend is a valve-sparing root repair or replacement as well as preserving or restoring the diameter of the aortic annulus and sinutubular junction. Read More

View Article

Download full-text PDF

Source
August 2012
2 Reads

Editorial: focus on cardiovascular disease, diabetes and vessel fibrosis.

Authors:
Paul J Higgins

Recent Pat Cardiovasc Drug Discov 2012 Apr;7(1)

View Article

Download full-text PDF

Source
April 2012
2 Reads

Stent selection in patients with myocardial infarction: drug eluting, biodegradable polymers or bare metal stents?

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):105-20

Cardiovascular Research Center, Cardiac Unit, Otamendi Hospital, Buenos Aires, Argentina.

Percutaneous coronary intervention (PCI) has been increasingly used in the last years during interventional procedures in patients with acute coronary syndromes (ACS) including ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). In patients with either STEMI, NSTEMI, high risk ACS with EKG changes or cardiac enzymes rises; PCI with bare metal stent (BMS) implantation has been associated with a significant improvement in clinical outcome. Therefore, BMS implantation during primary PCI in STEMI has become a standard of practice. Read More

View Article

Download full-text PDF

Source
August 2012
8 Reads

HDL-C levels and cardiovascular disease: more is not always better!

Recent Pat Cardiovasc Drug Discov 2012 Aug;7(2):121-33

Instituto de Investigaciones Cardiológicas Alberto C. Taquini (UBA-CONICET), Buenos Aires, Argentina.

HMG-CoA reductase inhibitors have consistently demonstrated a relative risk reduction of death and myocardial infarction ranging between 29 and 35%. Nevertheless, in spite of significant improvement in prevention, cardiovascular disease remains the main cause of morbidity and mortality in industrialized countries. This significant residual risk observed in approximately 70% of patients under optimal anti-atherosclerotic therapies, warrants the exploration and development of alternative cardiovascular drugs. Read More

View Article

Download full-text PDF

Source
August 2012
2 Reads